|

INO Stock Price: Inovio Pharmaceuticals Inc. attracting bargain-seekers after earnings-related crash

  • NASDAQ:INO falls slightly by 0.54% alongside the Nasdaq index.

  • Investors await the earnings call next week for an update on its COVID-19 vaccine. 

  • Inovio Pharmaceuticals Inc is attempting recovery on Wednesday after crashing on Tuesday.

Update 2: INO has been making its way up in Wednesday's pre-trading session, nearing the $15 mark. Bargain-seekers seem to find Inovio's stock attractive after it collapsed by 23% to $14.62 on Tuesday, following the disappointing earnings report – that left more questions than answers. The crash of gold may make smaller stocks more attractive. 

Update: NASDAQ: INO is changing hands at around $15 – a fall of around 20% from Monday's close. The move comes after Inovio published disappointing second-quarter earnings. Analysts at Stifel slashed INO's price from $24 to $16 – and it is already below that level. Uncertainty is looming over the next steps in the pharm firm's coronavirus vaccine trial. The fall is exacerbated by Russia's announcement of registering a COVID-19 vaccine.

It has been a stellar twelve months for NASDAQ: INO investors as the stock has risen by over 750% during that time. On Friday, Inovio closed out the week on a flat note as it shaved 0.54% off of its stock price – ending the week at $20.22. The trading volume was relatively low as it seems that most investors are awaiting the quarterly earnings call on Monday

Wall Street analysts are estimating a second-quarter earnings-per-share loss of $0.17 which is far worse than Inovio’s second-quarter loss of $0.03 per share from 2019. If Inovio is able to match or beat the earnings estimates, it would be reporting an increase in earnings of over 40% year over year. 

As far as Operation Warp Speed and the race for the coronavirus vaccine goes, it is unclear where Inovio stands in the big picture. INO is extremely innovative with its vaccine development and its process for the potential COVID-19 vaccine INO-4800 – has been no different. Rather than injecting patients with parts of the actual virus, Inovio has developed a way to administer DNA that includes antigens. The body reads them and is then able to create them, meaning that if the coronavirus ever enters the body – the patient’s immune system would automatically begin to create more antigens in response. 

INO Stock Forecast

Inovio investors must be wondering why the company has not been chosen for one of the $1 billion handouts that other pharmaceutical companies like Johnson and Johnson (NYSE:JNJ), GlaxoSmithKline (NYSE:GSK) – and even comparably sized rival Novavax (NASDAQ:NVAX) – have received. Time may be running out for Inovio to become a viable competitor in Operation Warp Speed, and investors should be provided with a status update at its earnings call on Monday

Author

More from Stocks Reporter
Share:

Editor's Picks

GBP/USD clings to multi-day peaks below 1.3500

GBP/USD trades with marked gains on Friday, now giving away some gains following an earlier surpass of the key 1.3500 yardstick. Indeed, Cable gathers fresh steam amid the strong offered stance in the Greenback, all after US NFP badly missed expectations in July.

EUR/USD: Post-NFP bounce falters around 1.1580

EUR/USD reverses Thursday’s decline and trades with solid gains in the 1.1560 region, or two-month peaks, on Friday. The pair’s firm performance comes in a context of a sharp correction in the US Dollar as investors continue to assess disheartening US NFP readings.

How Wall Street rigs the game [Video]

In this week’s Live from the Vault, Andrew Maguire is joined by Peter Antico and Sean Stone to discuss the Paradigm of Money - an in-depth expose of financial market corruption, from naked shorting to the two-tier system that protects Wall Street.

XRP Price Forecast: XRP nears critical $1.00 support
Ripple (XRP) remains pressured on Friday, trading around $1.03 at the time of writing. The token appears to hold this current level as support but lacks a catalyst to sustain a knee-jerk rebound toward the next key resistance at $1.10.
Is Gold about to enter its biggest bull run since 2020?
Gold has stormed back into the spotlight and its next move could leave late buyers chasing. On August 5, the yellow metal surged almost 7% – roughly $174 – to close near $4,308 an ounce, posting one of its biggest daily advances in recent history. A weaker U.S dollar, falling Treasury yields, changing Federal Reserve expectations and renewed safe-haven demand all struck at once.
9-3: Is the Federal Reserve’s vote tally Warsh's new forward guidance?
The rate did not move. Neither did the statement, and that’s the more interesting fact. Set the July 29 Federal Open Market Committee (FOMC) statement beside the one issued on June 17, and the two documents are identical apart from a single verb and a paragraph at the bottom naming three dissenters.